Menorrhagia, characterized by excessive menstrual blood loss, significantly impairs the quality of life of women worldwide. This multi-centric clinical study evaluated the safety and efficacy of Qurs-e-Habis, a traditional Unani pharmacopeial formulation, in managing menorrhagia. Conducted across three specialized Unani research centres, the study enrolled 168 non-gravid women aged 18–45 years presenting with menorrhagia defined by menstrual blood loss exceeding 80 ml per cycle. Participants received oral Qurs-e-Habis (250 mg twice daily) for 12 weeks. Efficacy outcomes included menstrual blood loss reduction measured via a modified menstrual pictogram and pain severity assessed by Visual Analog Scale, alongside quality of life and hematological parameters. The treatment resulted in a statistically significant mean blood loss reduction of 57.1% and a concomitant 59.7% decrease in pain scores by study completion. Clinical success, denoted by ≥30% improvement, was achieved in 78.6% of participants. Secondary benefits included improved menstrual cycle regularity, normalized hemoglobin levels, and enhanced functional status. The safety profile was favourable, with only mild and transient adverse events reported, and no hepatotoxicity or nephrotoxicity observed. Younger age, shorter symptom duration, and normal BMI were predictors of better treatment response. The findings substantiate Qurs-e-Habis as a safe, effective, and well-tolerated therapeutic option for menorrhagia, offering a promising alternative to conventional treatments with fewer side effects.
Shaikh et al. (Mon,) studied this question.